At Rubedo Life Sciences, we developed a novel concept of intelligent discovery platform combined with recombinant chemistry to selectively target specific cell types of the body, without toxicity or side effects.
The first product line developed by Rubedo labs is based on smart molecules that can target a population of pro-inflammatory cells that accumulate in the body with age, called “Senescent Cells”. These cells cause increased chronic inflammation, pain, and tissue decay that contribute to age-related diseases like Diabetes, Alzheimer’s, Cardio-Vascular Diseases and Cancer.
By selectively clearing the body of these cells, while preserving adjacent healthy cells, the tissues start to rejuvenate and diseases revert to improved healthy states.
The first of our therapeutic approaches is designed to target these senescent cells (which are normally locked in their cell cycle state called G0) by inducing them to die through a mechanism called apoptosis. By doing so, the body will be specifically cleared of these senescent cells without affecting the other healthy cells present in our bodies.
The consequence of this are rejuvenative effects that restores health.
Our initial indications are:
Other pipelines in the discovery phase focus on targeting other cell types other than senescence cells, such as stem cells to activate their regenerative potential, progressively lost with age and diseases.